Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 130Thoracic 44Head & Neck 27Breast 23Sarcoma 22Gynecologic 21CNS 6Dermatologic 5Endocrine 4Other solid neoplasm 3Tumor-Agnostic 2Genitourinary 2Other neoplasm 1NET 1Lymphoid 1

Conditions

Adrenocortical Carcinoma 2Radioactive Iodine-refractory Differentiated Thyroid Cancer 1Neuroendocrine Tumors 1Adrenal Gland Neoplasms 1

Interventions

Everolimus 27pembrolizumab 25Temozolomide 24lutetium Lu 177 dotatate 22Nivolumab 18Magnetic Resonance Spectroscopy 18lenvatinib 17cabozantinib 17Cisplatin 16Sunitinib 15Capecitabine 14Bevacizumab 14Specimen Handling 12Sorafenib 12trametinib 10Ipilimumab 10Etoposide 10pasireotide 9dabrafenib 9Paclitaxel 9Carboplatin 8pazopanib 7lanreotide 7Octreotide 7Fluorodeoxyglucose F18 7anlotinib 6Irinotecan 6Injections 6Doxorubicin 6surufatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × apatinib × Endocrine × Clear all
NCT04560127 2025-07-10

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

Peking Union Medical College Hospital

Phase 2 Active not recruiting
20 enrolled
EndocrineHead & Neck

Radioactive Iodine-refractory Differentiated Thyroid Cancer

NCT06831175 2025-06-03

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

West China Hospital

Phase 2 Recruiting
28 enrolled
Endocrine

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

NCT06764368 2025-01-08

Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors

Beijing Chest Hospital

Phase 2 Not yet recruiting
39 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04318730 2024-07-17

Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma

West China Hospital

Phase 2 Recruiting
21 enrolled
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡